Last reviewed · How we verify

CAPOX/SOX/FOLFOX — Competitive Intelligence Brief

CAPOX/SOX/FOLFOX (CAPOX/SOX/FOLFOX) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen (fluoropyrimidine + platinum agent). Area: Oncology.

phase 3 Combination chemotherapy regimen (fluoropyrimidine + platinum agent) Thymidylate synthase (5-FU); DNA (oxaliplatin cross-linking) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CAPOX/SOX/FOLFOX (CAPOX/SOX/FOLFOX) — Fujian Cancer Hospital. CAPOX/SOX/FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CAPOX/SOX/FOLFOX TARGET CAPOX/SOX/FOLFOX Fujian Cancer Hospital phase 3 Combination chemotherapy regimen (fluoropyrimidine + platinum agent) Thymidylate synthase (5-FU); DNA (oxaliplatin cross-linking)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen (fluoropyrimidine + platinum agent) class)

  1. Fujian Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CAPOX/SOX/FOLFOX — Competitive Intelligence Brief. https://druglandscape.com/ci/capox-sox-folfox. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: